Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves non-opioid pain medication
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.
FDA approves first non-opioid pain medicine in more than 20 years
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time in over two decades that the agency has approved a non-opioid pain drug with a novel mechanism of action.
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
Psychology Today
1d
Treating Pain—Avoiding the Brain
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
1d
FDA approves opiate-alternative acute pain management drug, local experts share their thoughts
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare ...
News Medical on MSN
18h
Pain coping skills training reduces pain and improves quality of life for dialysis patients
People undergoing hemodialysis treatment for kidney failure often experience chronic pain related to their condition, but it ...
Healio
1d
FDA approves nonopioid Journavx for moderate to severe acute pain
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Journavx
Food and Drug Administration
Feedback